科研动态PubMed 摘要

lncRNA H19在胃癌中的预后价值:系统评价与Meta分析。

PubMed 学科轮询 · 2026-10-19

完整摘要 · 中文译文

LncRNA H19是胃癌(GC)中关键的调控因子,可作为患者预后的有吸引力的生物标志物。本荟萃分析旨在评估lncRNA H19表达水平与患者预后及临床病理特征之间的联系。采用HR和95%CI评估lncRNA H19表达与GC患者预后及临床病理特征之间的联系。通过数据库预测了涉及lncRNA H19的生物信息学分析、潜在分子机制及药物治疗。通过qRT-PCR验证了lncRNA H19在GC细胞中的表达。lncRNA H19高表达与GC患者较低的总生存率相关,并与其TNM分期、淋巴结转移和肿瘤侵袭相关。生物信息学分析证实lncRNA H19在GC中显著表达并与不良预后相关。功能预测分析提示lncRNA H19可能通过ceRNA调控网络、转录因子(TFs)以及与RNA结合蛋白(RBPs)的预测相互作用促进GC进展。Nutlin-3、PD-0332991和Topotecan被预测为初步候选药物。LncRNA H19被证实在GC细胞中高表达。LncRNA H19可能作为GC预后预测的可行生物标志物,值得在临床研究中进一步验证。

完整摘要 · 英文原文

LncRNA H19 is a crucial regulatory player in GC and could operate as an attractive biomarker for patient prognosis. This meta-analysis aims to gauge the link between lncRNA H19 expression levels and patient prognosis, as well as clinicopathological features. HR and 95%CI were utilized to evaluate the connection between lncRNA H19 expression and prognosis, as well as clinicopathological features in GC patients. Bioinformatics analysis, potential molecular mechanisms and drug therapy involving lncRNA H19 were predicted through databases. The expression of lncRNA H19 in GC cells was verified through qRT-PCR. High expression of lncRNA H19 is correlated with a lower overall survival rate in GC patients, as well as TNM stage, lymph node metastasis and tumor invasion. Bioinformatics analysis confirmed that lncRNA H19 is significantly expressed in GC and related to poor prognosis. Function prediction analyses suggested that lncRNA H19 may contribute to GC progression through ceRNA regulatory networks, TFs, and predicted interactions with RBPs. Nutlin-3, PD-0332991, and Topotecan were predicted as preliminary candidate drugs. LncRNA H19 was confirmed to be highly expressed in GC cells. LncRNA H19 might act as a feasible biomarker for prognostic prediction in GC, warranting further validation in clinical studies.

English
Prognostic Value of lncRNA H19 in Gastric Cancer: A Systematic Review and Meta-Analysis.
内容仅供参考,不构成诊疗建议,不能替代执业医师的诊断。

← 返回元界